The Biomarker Tests Market is expected to register a CAGR of 11.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Application (Cancer, Cardiovascular, Infectious Diseases, Central Nervous System, Others). The report is segmented by End User (Pharma and Biotech Companies, Diagnostic Companies, Healthcare IT Companies, Clinical Laboratories). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Biomarker Tests Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Biomarker Tests Market Segmentation
Application- Cancer
- Cardiovascular
- Infectious Diseases
- Central Nervous System
- Others
- Pharma and Biotech Companies
- Diagnostic Companies
- Healthcare IT Companies
- Clinical Laboratories
Strategic Insights
Biomarker Tests Market Growth Drivers- Advances in Precision Medicine: Advances in precision medicine, that is, the alignment of medical treatment with individualized characteristics for each patient, are picking up speed in all health-care systems. Precision medicine offers molecular insights into a patient's genetic makeup, disease pathogenesis, and how they will respond to certain therapies using biomarker tests. These tests help healthcare providers tailor treatment plans that are more potent with fewer side effects. Growth has been so rapid of genomics, proteomics, and other omics technologies that have driven further biomarker development and testing.
- Testing platforms: Next-generation sequencing, liquid biopsy, and digital PCR represent the latest breakthroughs in testing platforms that have enhanced the sensitivity, specificity, and speed of biomarker tests. Such technological advancement allows for faster, more accurate detection of biomarkers at much cheaper costs. Testing platforms remain always advancing, such that increasingly applications of biomarker testing in clinical practice are to be non-invasive and real-time.
- Increasing demand for early diagnostics and preventive health care: Disease diagnosis now focuses on the very early stages. It offers better possibilities of treatment and is cheaper in the long run. Biomarker-based tests thus play a crucial role in disease detection in its very nascent stages when symptoms have not yet been produced. Detection of cancers has become much earlier than ever before through liquid biopsy or blood biopsy: testing for tumor DNA in the bloodstream: and transformed the face of cancer diagnostics. As medicine continues along the way to prevention rather than cure, the need for biomarkers that provide better detection at earlier stages is sure to be continued and sustained.
- Integration of Artificial Intelligence (AI) and Machine Learning (ML): Biomarker discovery and testing has been transformed by the introduction of innovative AI and ML technologies that enhance the interpretation of large datasets. Identification of novel biomarkers along with the risks related to diseases, as well as complicated analysis of test results, are now possible through AI-powered platforms. Applications of these technologies can enable firms to streamline business workflows; reduce human errors, and improve accuracy associated with the use of their biomarker tests for more trustful use in clinical settings.
- Growth of Liquid Biopsy for Non-Invasive Testing: Another significant trend is liquid biopsy, which is growing really fast as the next key area in biomarker testing, especially in the field of oncology. Liquid biopsy is a non-invasive method whereby one uses blood or other bodily fluids to detect cancer-related biomarkers for identifying genetic mutations or tumor DNA with minimal patient discomfort. Liquid biopsy is increasingly popular because it offers several advantages over the conventional tissue biopsy: it gives quicker results, allows for the possible repetition in monitoring of disease progression, and allows the tracking of real-time changes in the tumor microenvironment.
- Expansion of CDx: The tests are performed in concert with particular therapies to predict a patient's response to the treatment. This trend is more evident in oncology: CDx tests are being used to identify which patients are most likely to benefit from targeted therapies, immunotherapies, or tailored treatment regimens. As regulatory approvals of CDx tests accelerate with increasing collaboration between diagnostic companies and pharmaceutical manufacturers, this brings biomarker tests closer to personalized treatment plans.
- Development of Multi Biomarker Panels: Multi biomarker panels are coming back as one of the promising diagnostic tools in the management of complex diseases such as cancer, cardiovascular diseases, and neurological disorders. Multiple testing of several biomarkers at a time details out the mechanism of the disease and hence improves the specificity of diagnosis. Expensive and cumbersome multi: biomarker tests are market opportunities, especially in the early stages of the disease and in treatment: monitoring personalized care.
- Higher application in Clinical Trials: Biomarker tests find applications in clinical trials to monitor the responses of treatment, identify suitable patients, and track the progression of disease. From this aspect, there are opportunities for companies to develop and commercialize the appropriate biomarkers that could be tailored specifically to meet the challenges of clinical research. Hence, as the pharmaceutical industry continues to weigh heavily the pursuit of personalized medicine, it can expect biomarkers tests to significantly contribute toward identifying the best population of candidates for clinical trials, thus hastening drug development and approval.
- Emerging Markets in Asia-Pacific and Latin America: The growth of the market is relatively high for biomarker tests in emerging markets. Its availability in many regions, specifically Asia- Pacific and Latin America, is increasing health care infrastructure, especially for advanced diagnostic tools. The opportunities that are thus created by these areas are immense, for developers of biomarker tests to expand their presence there and additionally cater to unmet healthcare needs. High healthcare investments as well as the emerging middle class have been promoting the application of biomarker testing in these regions.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Biomarker Tests Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Biomarker Tests Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Cancer segment, by applications, dominated the market in 2023.
Players operating in the market are GLAXOSMITHKLINE PLC, GE HEALTHCARE, PFIZER INC., NOVARTIS AG, MEDTRONIC PLC, F. HOFFMANN-LA ROCHE AG, QUEST DIAGNOSTICS, QIAGEN N.V., BECTON DICKINSON, BIO-RAD LABORATORIES
North America region dominated the Biomarker Testsmarket in 2023.
Development of Multi-Biomarker Panels act as a opportunity for growth of the market in forecast period.
The Biomarker Tests Market is estimated to witness a CAGR of 11.5% from 202#to 2031
The major factors driving the Biomarker Testsmarket are:
1. Advances in Precision Medicine
2. Increasing demand for early diagnostics and preventive health care
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Biomarker Tests Market - By Application
1.3.2 Biomarker Tests Market - By End User
1.3.3 Biomarker Tests Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BIOMARKER TESTS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BIOMARKER TESTS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. BIOMARKER TESTS MARKET - GLOBAL MARKET ANALYSIS
6.1. BIOMARKER TESTS - GLOBAL MARKET OVERVIEW
6.2. BIOMARKER TESTS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. BIOMARKER TESTS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
7.1. OVERVIEW
7.2. APPLICATION MARKET FORECASTS AND ANALYSIS
7.3. CANCER
7.3.1. Overview
7.3.2. Cancer Market Forecast and Analysis
7.4. CARDIOVASCULAR
7.4.1. Overview
7.4.2. Cardiovascular Market Forecast and Analysis
7.5. INFECTIOUS DISEASES
7.5.1. Overview
7.5.2. Infectious Diseases Market Forecast and Analysis
7.6. CENTRAL NERVOUS SYSTEM
7.6.1. Overview
7.6.2. Central Nervous System Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. BIOMARKER TESTS MARKET - REVENUE AND FORECASTS TO 2028 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. PHARMA AND BIOTECH COMPANIES
8.3.1. Overview
8.3.2. Pharma and Biotech Companies Market Forecast and Analysis
8.4. DIAGNOSTIC COMPANIES
8.4.1. Overview
8.4.2. Diagnostic Companies Market Forecast and Analysis
8.5. HEALTHCARE IT COMPANIES
8.5.1. Overview
8.5.2. Healthcare IT Companies Market Forecast and Analysis
8.6. CLINICAL LABORATORIES
8.6.1. Overview
8.6.2. Clinical Laboratories Market Forecast and Analysis
9. BIOMARKER TESTS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Biomarker Tests Market Overview
9.1.2 North America Biomarker Tests Market Forecasts and Analysis
9.1.3 North America Biomarker Tests Market Forecasts and Analysis - By Application
9.1.4 North America Biomarker Tests Market Forecasts and Analysis - By End User
9.1.5 North America Biomarker Tests Market Forecasts and Analysis - By Countries
9.1.5.1 United States Biomarker Tests Market
9.1.5.1.1 United States Biomarker Tests Market by Application
9.1.5.1.2 United States Biomarker Tests Market by End User
9.1.5.2 Canada Biomarker Tests Market
9.1.5.2.1 Canada Biomarker Tests Market by Application
9.1.5.2.2 Canada Biomarker Tests Market by End User
9.1.5.3 Mexico Biomarker Tests Market
9.1.5.3.1 Mexico Biomarker Tests Market by Application
9.1.5.3.2 Mexico Biomarker Tests Market by End User
9.2. EUROPE
9.2.1 Europe Biomarker Tests Market Overview
9.2.2 Europe Biomarker Tests Market Forecasts and Analysis
9.2.3 Europe Biomarker Tests Market Forecasts and Analysis - By Application
9.2.4 Europe Biomarker Tests Market Forecasts and Analysis - By End User
9.2.5 Europe Biomarker Tests Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Biomarker Tests Market
9.2.5.1.1 Germany Biomarker Tests Market by Application
9.2.5.1.2 Germany Biomarker Tests Market by End User
9.2.5.2 France Biomarker Tests Market
9.2.5.2.1 France Biomarker Tests Market by Application
9.2.5.2.2 France Biomarker Tests Market by End User
9.2.5.3 Italy Biomarker Tests Market
9.2.5.3.1 Italy Biomarker Tests Market by Application
9.2.5.3.2 Italy Biomarker Tests Market by End User
9.2.5.4 Spain Biomarker Tests Market
9.2.5.4.1 Spain Biomarker Tests Market by Application
9.2.5.4.2 Spain Biomarker Tests Market by End User
9.2.5.5 United Kingdom Biomarker Tests Market
9.2.5.5.1 United Kingdom Biomarker Tests Market by Application
9.2.5.5.2 United Kingdom Biomarker Tests Market by End User
9.2.5.6 Rest of Europe Biomarker Tests Market
9.2.5.6.1 Rest of Europe Biomarker Tests Market by Application
9.2.5.6.2 Rest of Europe Biomarker Tests Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Biomarker Tests Market Overview
9.3.2 Asia-Pacific Biomarker Tests Market Forecasts and Analysis
9.3.3 Asia-Pacific Biomarker Tests Market Forecasts and Analysis - By Application
9.3.4 Asia-Pacific Biomarker Tests Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Biomarker Tests Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Biomarker Tests Market
9.3.5.1.1 Australia Biomarker Tests Market by Application
9.3.5.1.2 Australia Biomarker Tests Market by End User
9.3.5.2 China Biomarker Tests Market
9.3.5.2.1 China Biomarker Tests Market by Application
9.3.5.2.2 China Biomarker Tests Market by End User
9.3.5.3 India Biomarker Tests Market
9.3.5.3.1 India Biomarker Tests Market by Application
9.3.5.3.2 India Biomarker Tests Market by End User
9.3.5.4 Japan Biomarker Tests Market
9.3.5.4.1 Japan Biomarker Tests Market by Application
9.3.5.4.2 Japan Biomarker Tests Market by End User
9.3.5.5 South Korea Biomarker Tests Market
9.3.5.5.1 South Korea Biomarker Tests Market by Application
9.3.5.5.2 South Korea Biomarker Tests Market by End User
9.3.5.6 Rest of Asia-Pacific Biomarker Tests Market
9.3.5.6.1 Rest of Asia-Pacific Biomarker Tests Market by Application
9.3.5.6.2 Rest of Asia-Pacific Biomarker Tests Market by End User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Biomarker Tests Market Overview
9.4.2 Middle East and Africa Biomarker Tests Market Forecasts and Analysis
9.4.3 Middle East and Africa Biomarker Tests Market Forecasts and Analysis - By Application
9.4.4 Middle East and Africa Biomarker Tests Market Forecasts and Analysis - By End User
9.4.5 Middle East and Africa Biomarker Tests Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Biomarker Tests Market
9.4.5.1.1 South Africa Biomarker Tests Market by Application
9.4.5.1.2 South Africa Biomarker Tests Market by End User
9.4.5.2 Saudi Arabia Biomarker Tests Market
9.4.5.2.1 Saudi Arabia Biomarker Tests Market by Application
9.4.5.2.2 Saudi Arabia Biomarker Tests Market by End User
9.4.5.3 U.A.E Biomarker Tests Market
9.4.5.3.1 U.A.E Biomarker Tests Market by Application
9.4.5.3.2 U.A.E Biomarker Tests Market by End User
9.4.5.4 Rest of Middle East and Africa Biomarker Tests Market
9.4.5.4.1 Rest of Middle East and Africa Biomarker Tests Market by Application
9.4.5.4.2 Rest of Middle East and Africa Biomarker Tests Market by End User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Biomarker Tests Market Overview
9.5.2 South and Central America Biomarker Tests Market Forecasts and Analysis
9.5.3 South and Central America Biomarker Tests Market Forecasts and Analysis - By Application
9.5.4 South and Central America Biomarker Tests Market Forecasts and Analysis - By End User
9.5.5 South and Central America Biomarker Tests Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Biomarker Tests Market
9.5.5.1.1 Brazil Biomarker Tests Market by Application
9.5.5.1.2 Brazil Biomarker Tests Market by End User
9.5.5.2 Argentina Biomarker Tests Market
9.5.5.2.1 Argentina Biomarker Tests Market by Application
9.5.5.2.2 Argentina Biomarker Tests Market by End User
9.5.5.3 Rest of South and Central America Biomarker Tests Market
9.5.5.3.1 Rest of South and Central America Biomarker Tests Market by Application
9.5.5.3.2 Rest of South and Central America Biomarker Tests Market by End User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL BIOMARKER TESTS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. BIOMARKER TESTS MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. GE HEALTHCARE
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. PFIZER INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. NOVARTIS AG
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. MEDTRONIC PLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE AG
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. QUEST DIAGNOSTICS
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. QIAGEN N.V.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BECTON, DICKINSON
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. BIO-RAD LABORATORIES
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
2. GE HEALTHCARE
3. PFIZER INC.
4. NOVARTIS AG
5. MEDTRONIC PLC
6. F. HOFFMANN-LA ROCHE AG
7. QUEST DIAGNOSTICS
8. QIAGEN N.V.
9. BECTON, DICKINSON
10. BIO-RAD LABORATORIES
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For